CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY - Get Free Report) reached a new 52-week low on Monday . The company traded as low as $3.91 and last traded at $3.91, with a volume of 37258591 shares changing hands. The stock had previously closed at $92.43.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the company. UBS Group raised CochLear from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 18th. Zacks Research raised CochLear to a "hold" rating in a research report on Monday, August 11th. Canaccord Genuity Group raised CochLear from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 7th. Finally, Citigroup lowered CochLear to a "neutral" rating in a research report on Thursday, September 18th. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, CochLear presently has an average rating of "Moderate Buy".
Get Our Latest Research Report on CochLear
CochLear Trading Down 1.4%
The business has a 50-day simple moving average of $97.60 and a 200 day simple moving average of $92.78.
CochLear Announces Dividend
The company also recently announced a dividend, which will be paid on Tuesday, October 28th. Stockholders of record on Monday, September 22nd will be given a $0.1045 dividend. The ex-dividend date of this dividend is Friday, September 19th. This represents a dividend yield of 122.0%.
CochLear Company Profile
(
Get Free Report)
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CochLear, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CochLear wasn't on the list.
While CochLear currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.